Drug Trial Radar · NCT05052255
RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
66
Actual
Start
Aug 13, 2021
Primary completion
Oct 2, 2025
Study completion Oct 2, 2025
Sponsor
- Lead sponsor
- Ryvu Therapeutics SAIndustry
- Sponsor type
- Industry
- First posted
- Sep 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1/2, dose-escalation and expansion study investigating the safety, pharmacokinetics, and efficacy of RVU120 (SEL120) in patients with metastatic or advanced solid tumors progressing from previous lines of therapy.
Conditions
- Advanced Solid Tumor
Interventions
RVU120Drug
RVU120 will be administered as a single oral dose every other day over a 3 week treatment cycle until disease progression or unacceptable toxicity and an alternative daily dosing schedule will also be tested.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events in part ITime frame: Up to 2 years
- Dose Finding in part ITime frame: Up to 2 years
- Objective Overall Response in part IITime frame: Up to 2 years
- Duration of Response in part IITime frame: Up to 2 years
- Progression Free Survival in part IITime frame: Up to 2 years
- Overall Survival in part IITime frame: Up to 2 years
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Beskidzkie Centrum Onkologii, Szpital Miejski im.
Bielsko-Biala, Poland
Medical University Early Phase 1 Research Center / Uniwersyteckie Centrum Kliniczne Ośrodek Badań Klinicznych Wczesnych Faz
Gdansk, Poland
UCK im. prof. K. Gibińskiego
Katowice, Poland
Maria Sklodowska-Curie National Research Institute of Oncology / Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy
Warsaw, Poland
Next Oncology Hospital Quironsalud Barcelona
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Next Oncology Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.